CR20150211A - Compuestos diméricos - Google Patents
Compuestos diméricosInfo
- Publication number
- CR20150211A CR20150211A CR20150211A CR20150211A CR20150211A CR 20150211 A CR20150211 A CR 20150211A CR 20150211 A CR20150211 A CR 20150211A CR 20150211 A CR20150211 A CR 20150211A CR 20150211 A CR20150211 A CR 20150211A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- dimerical
- cancer
- formula
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
Abstract
Se dan a conocer compuestos de fórmula I: o sales farmacéuticamente aceptables de los mismos, en los que Z, X, Q y R1 se definen en la presente solicitud, y métodos de utilización de dichos compuestos en el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261735684P | 2012-12-11 | 2012-12-11 | |
| PCT/EP2013/075874 WO2014090709A1 (en) | 2012-12-11 | 2013-12-09 | Dimeric compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150211A true CR20150211A (es) | 2015-05-29 |
Family
ID=49726780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150211A CR20150211A (es) | 2012-12-11 | 2015-04-22 | Compuestos diméricos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9409888B2 (es) |
| EP (1) | EP2931719B1 (es) |
| JP (1) | JP6309536B2 (es) |
| KR (1) | KR20150093228A (es) |
| CN (1) | CN104854100B (es) |
| AU (1) | AU2013357493A1 (es) |
| CA (1) | CA2887497A1 (es) |
| CL (1) | CL2015001374A1 (es) |
| CO (1) | CO7350640A2 (es) |
| CR (1) | CR20150211A (es) |
| EA (1) | EA201591024A1 (es) |
| IL (1) | IL238968A0 (es) |
| MA (1) | MA38240B1 (es) |
| MX (1) | MX2015007053A (es) |
| PE (1) | PE20151083A1 (es) |
| PH (1) | PH12015501088A1 (es) |
| SG (1) | SG11201503718QA (es) |
| WO (1) | WO2014090709A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| US9422331B2 (en) * | 2012-09-19 | 2016-08-23 | Hoffmann-La Roche Inc. | 2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer |
| JP6680683B2 (ja) | 2013-11-18 | 2020-04-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロ−ベンゾジアゼピノン類 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP6787331B2 (ja) * | 2015-10-02 | 2020-11-18 | 日本ゼオン株式会社 | 酸ハライド溶液の製造方法、混合溶液、及びモノエステル化合物の製造方法 |
| CA3020792A1 (en) | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| CA3148504A1 (en) | 2019-08-08 | 2021-02-11 | Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center | Combination therapy for treatment of cancer |
| US20240382600A1 (en) | 2021-09-01 | 2024-11-21 | Novartis Ag | Bifunctional degraders comprising a tead binder |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI404537B (zh) * | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| AU2008321770B2 (en) * | 2007-11-16 | 2012-09-06 | Ube Industries, Ltd. | Benzazepinone compound |
| WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| EP2784076A1 (en) * | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
| US9422331B2 (en) * | 2012-09-19 | 2016-08-23 | Hoffmann-La Roche Inc. | 2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer |
-
2013
- 2013-12-09 AU AU2013357493A patent/AU2013357493A1/en not_active Abandoned
- 2013-12-09 SG SG11201503718QA patent/SG11201503718QA/en unknown
- 2013-12-09 MX MX2015007053A patent/MX2015007053A/es unknown
- 2013-12-09 MA MA38240A patent/MA38240B1/fr unknown
- 2013-12-09 EA EA201591024A patent/EA201591024A1/ru unknown
- 2013-12-09 KR KR1020157018397A patent/KR20150093228A/ko not_active Withdrawn
- 2013-12-09 CN CN201380064764.0A patent/CN104854100B/zh not_active Expired - Fee Related
- 2013-12-09 CA CA 2887497 patent/CA2887497A1/en not_active Abandoned
- 2013-12-09 US US14/648,282 patent/US9409888B2/en not_active Expired - Fee Related
- 2013-12-09 PE PE2015000907A patent/PE20151083A1/es not_active Application Discontinuation
- 2013-12-09 JP JP2015546960A patent/JP6309536B2/ja not_active Expired - Fee Related
- 2013-12-09 EP EP13802359.3A patent/EP2931719B1/en not_active Not-in-force
- 2013-12-09 WO PCT/EP2013/075874 patent/WO2014090709A1/en not_active Ceased
-
2015
- 2015-04-17 CO CO15086489A patent/CO7350640A2/es unknown
- 2015-04-22 CR CR20150211A patent/CR20150211A/es unknown
- 2015-05-15 PH PH12015501088A patent/PH12015501088A1/en unknown
- 2015-05-20 CL CL2015001374A patent/CL2015001374A1/es unknown
- 2015-05-21 IL IL238968A patent/IL238968A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1213543A1 (zh) | 2016-07-08 |
| MX2015007053A (es) | 2015-09-28 |
| EA201591024A1 (ru) | 2015-09-30 |
| EP2931719B1 (en) | 2017-01-25 |
| JP2016502986A (ja) | 2016-02-01 |
| MA38240A1 (fr) | 2018-02-28 |
| IL238968A0 (en) | 2015-07-30 |
| WO2014090709A1 (en) | 2014-06-19 |
| PH12015501088A1 (en) | 2015-08-03 |
| CN104854100A (zh) | 2015-08-19 |
| SG11201503718QA (en) | 2015-06-29 |
| CO7350640A2 (es) | 2015-08-10 |
| EP2931719A1 (en) | 2015-10-21 |
| CA2887497A1 (en) | 2014-06-19 |
| PE20151083A1 (es) | 2015-08-06 |
| CN104854100B (zh) | 2017-05-24 |
| KR20150093228A (ko) | 2015-08-17 |
| US9409888B2 (en) | 2016-08-09 |
| AU2013357493A1 (en) | 2015-04-30 |
| MA38240B1 (fr) | 2018-09-28 |
| JP6309536B2 (ja) | 2018-04-11 |
| CL2015001374A1 (es) | 2015-09-25 |
| US20160024055A1 (en) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150211A (es) | Compuestos diméricos | |
| CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
| NI201500140A (es) | Compuestos y composiciones terapéuticos | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| CR20140525A (es) | Compuestos de N-alquiltriazol como antagonistas de LPAR | |
| CR20140166A (es) | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1 | |
| EA201590296A1 (ru) | Дейтерированный ибрутиниб | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| CL2013003313A1 (es) | Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8. | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| MX361499B (es) | Baricitinib deuterado. | |
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| DOP2015000060A (es) | Profármacos de aminoquinazolina inhibidora de cinasa | |
| DOP2015000059A (es) | Amino-quinolinas como inhibidores de cinasa | |
| CR20140367A (es) | Inhibidores de iap | |
| MX2015009479A (es) | Compuestos y metodos para tratar infecciones bacterianas. | |
| EA201491609A1 (ru) | Модуляторы x рецепторов печени | |
| BR112017008481A2 (pt) | composto antimicótico | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| CR20150041A (es) | Azaheterociclos como inhibidores de bir2 y/o bir3 | |
| CR20150148A (es) | Azaindolinas | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina |